ATB-320

ATB-320
Product Description

[Immune Targeting Dual MOA anti-cancer agent] - Pre-clinical toxicology, TK, and safety pharmacology studies are ongoing and expect to be approved for Phase I IND by US FDA in 1st quarter of 2023 1. Confirmation of the synergistic effect of combination therapy with PD-1 & cytotoxic drugs in pre-clinical study 2. Targeting the undruggable with ASO which is difficult to be modulated by antibodies or small molecules 2. Increase binding affinity (efficacy) and plasma stability (half-life) through chemical modification 3. Secure the efficacy and safety data for pancreatic cancer and bile duct cancer compared to the standard therapy in pre-clinical study

Read more Show less

Autotelic Bio

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile
Specifications
  • Supplied from
    Korea, Republic Of
More specifications Fewer specifications
Sales Markets
Show more Show less

Autotelic Bio

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Autotelic Bio (5)

  • ATB-101

    Product ATB-101

    ATB-101 is the world’s first fixed-dose combination of olmesartan and dapagliflozin, designed for patients with hypertension and type 2 diabetes. A Phase 3 study has been completed in Korea, with regulatory approval expected in Q1 2027. U.S. development is progressing through the FDA 505(b)(2) pathway, wit...
  • ATB-301

    Product ATB-301

    [TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib 1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients 2. Confirm the suppression of IL-2's side effect in combination therapy which is c...
  • ATB-330

    Product ATB-330

    [ALK5 inhibitor / Small Molecule / Develop for IPF and Fibrosis) - Complete to derivate the lead compound 1. Confirm the highest ALK5 selectivity with superior efficacy and PK profile through in-vivo tests compared to competitors (small molecule new drugs) 2. For IPF treatment, develop as inhalation...
  • ATB-720

    Product ATB-720

    ATB-720 is a first-in-class topical antisense oligonucleotide (ASO) candidate for atopic dermatitis. Designed to deliver targeted activity directly to the skin while minimizing systemic exposure, ATB-720 has demonstrated compelling preclinical efficacy and offers a novel, non-steroidal treatment approach.
  • ATB-810

    Product ATB-810

    ATB-810 is a first-in-class antisense oligonucleotide (ASO) candidate for the treatment of ALS and progressive multiple sclerosis. Powered by Autotelic Bio’s proprietary C-Duplex™ technology, it is designed to achieve broad brain distribution and improved tolerability, with compelling efficacy demonstrated...